Pipeline ExpansionExtra-hepatic pipeline expansion shows visible progress with high-value programs like ARO-RAGE, ARO-DM1, ARO-DUX4, and ARO-INHBE.
Positive Clinical DataThe trial met its primary endpoint, with patients treated with 25 and 50 mg doses achieving significant triglyceride reductions compared to the placebo.
Strategic FinancingARWR announced securing $500M strategic financing facility with flexible 7-year repayment structure, which comes timely as management is on the cusp of executing on two key portfolio priorities.